1 active not recruiting, 1 enrolling by invitation, 1 not yet recruiting, 1 recruiting. 2 Not applicable, 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Enrolling by invitation 1, Not yet recruiting 1 |
| Phase 3 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Caigang Liu: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Sanyong Jiedu Granules in Treating Lumps-Type Non-Lactational Mastiti Sanyong Jiedu Granules, Standard Medication - Plasmacytic Mastitis, Granulomatous Lobular Mastitis | Not applicable | Not yet recruiting | Caigang Liu | 210 | 2026-03-20 | 2026-04-06 |
| Real-world Study on Shenbailing Granules for Improving Qi and Blood Deficiency in Patients After Breast Cancer Surgery Shenbailing - Breast Cancer | Not applicable | Enrolling by invitation | Caigang Liu | 2000 | 2024-12-30 | 2025-03-18 |
| Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer Cadonilimab (AK104) combined with chemotherapy and bevacizumab - Colorectal Cancer | Phase 3 | Recruiting | Caigang Liu | 30 | 2024-02-01 | 2024-08-22 |
| A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients ARX788, Pyrotinib maleate, Trastuzumab - HER2-positive Breast Cancer | Phase 2 / Phase 3 | Active not recruiting | Caigang Liu | 136 | 2022-05-23 | 2024-10-30 |
Breast Neoplasms (1) · Colorectal Neoplasms (1)
ARX788 (1) · Bevacizumab (1) · Carboplatin (1) · Docetaxel (1) · Drug Therapy (1) · Trastuzumab (1) · pertuzumab (1)
China (4)